Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
DAC HYP, Daclizumab high-yield process
print preview
bookmark
share with colleague
General Information
Company
Abbott Laboratories
Description
Humanized antibody against IL-2 receptor alpha chain (CD25)
Molecular Target
Interleukin-2 (IL-2) receptor alpha chain (CD25)
Mechanism of Action
Binds interleukin-2 (IL-2) receptor alpha chain (CD25); Antibody
Latest Stage of Development
Phase III
Indication
Multiple sclerosis (MS)
Partner
AbbVie Inc.
;
Biogen Idec Inc.
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy
General Information